Biomolecular and Clinical Frailty and Aging in Transplantation

Biomolecular and Clinical Frailty and Aging in Transplantation - Tx-Age

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00034042

Enrollment

200

Registered

2024-09-24

Start date

2024-10-11

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N18

Interventions

Group 1: Intervention group: CGA-based geriatric recommendations are discussed with the attending nephrologist and/or the primary care physician and also given to the patient Group 2: Control group: u

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: • Willingness to participate and written informed consent from the subject • Presentation in the transplant consultation for living donor evaluation or NTx waiting list of the UKK

Exclusion criteria

Exclusion criteria: • Refusal to participate in the study • Prefinal patients • Lack of consent

Design outcomes

Primary

Measure	Time frame
Changes in the biological and clinical frailty profile after 12 months	—

Secondary

Measure	Time frame
1.) Characterization of the frailty status of older patients with kidney failure (KF) (both on the transplant waiting list and of potential recipients and donors presenting for planned living donation) 2.) Comparison of four different frailty instruments with regard to their prognosis: the Multidimensional Prognostic Index (MPI), the Cologne Robustness Index (CRI), the Clinical Frailty Scale (CFS) and the Fried criteria 3.) Identification of high-risk patients and those who are likely to benefit from a kidney transplant (on the donor and recipient side) 4.) Mapping the dynamic progression of frailty in KF patients and kidney transplant patients 5.) Identification of starting points of frailty that enable improvement of frailty through prehabilitation or rehabilitation in later intervention studies 6.) Identification of biomarkers of frailty concerning metabolomics, microbiomics, transcriptomics, proteomics, (epi-)genomics, nucleolar-size, micronutrients and immunosenescence that are associated with risk profiles 7.) Assessment of the course of older KF patients with regard to secondary outcomes such as transplantation, mortality, hospitalization, Patient Related Outcome Measures (PROMs)	—

Measure

Time frame

1.) Characterization of the frailty status of older patients with kidney failure (KF) (both on the transplant waiting list and of potential recipients and donors presenting for planned living donation) 2.) Comparison of four different frailty instruments with regard to their prognosis: the Multidimensional Prognostic Index (MPI), the Cologne Robustness Index (CRI), the Clinical Frailty Scale (CFS) and the Fried criteria 3.) Identification of high-risk patients and those who are likely to benefit from a kidney transplant (on the donor and recipient side) 4.) Mapping the dynamic progression of frailty in KF patients and kidney transplant patients 5.) Identification of starting points of frailty that enable improvement of frailty through prehabilitation or rehabilitation in later intervention studies 6.) Identification of biomarkers of frailty concerning metabolomics, microbiomics, transcriptomics, proteomics, (epi-)genomics, nucleolar-size, micronutrients and immunosenescence that are associated with risk profiles 7.) Assessment of the course of older KF patients with regard to secondary outcomes such as transplantation, mortality, hospitalization, Patient Related Outcome Measures (PROMs)

—

Countries

Germany

Contacts

Public ContactAnna Maria Affeldt

Klinik II für Innere Medizin, Uniklinik Köln

anna.affeldt@uk-koeln.de+49 221 478 - 39265

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026